Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International, plc reported leadership changes effective January 10, 2026. The board appointed Ross Moat as chief operating officer and principal operating officer. He will keep overseeing commercial operations while taking on broader functional operations under the new title.
The board also appointed Eben Tessari as chief strategy officer, responsible for the company’s strategic, business development and technical operations, as well as its artificial intelligence initiatives. The company stated that there were no changes to the compensation arrangements for either executive in connection with these appointments.
Kiniksa Pharmaceuticals International, plc furnished an update on its 2025 financial performance. The company reported unaudited full-year 2025 ARCALYST net product revenue of $677.5 million. It also disclosed an unaudited gross-to-net figure of 8.4% for the year, indicating the difference between list prices and realized revenue after discounts and allowances. As of December 31, 2025, Kiniksa reported unaudited $414.1 million in cash, cash equivalents and short-term investments and stated that it had no debt. These figures were shared in a press release that is included as an exhibit.
Kiniksa Pharmaceuticals International, plc reported that its Chief Financial Officer, Mark Ragosa, sold 12,000 Class A ordinary shares on January 8, 2026. The sale was coded as an open-market disposition and was carried out at a weighted average price of $41.89 per share, through multiple trades within a disclosed price range. The transaction was completed under a pre-arranged Rule 10b5-1 trading plan that the reporting person executed on August 14, 2025, indicating the sale followed a preset schedule rather than ad hoc market timing. Following this transaction, the CFO directly beneficially owns 19,086 Class A ordinary shares of the company.
Kiniksa Pharmaceuticals International, plc director reports option exercise and share sale. On 12/15/2025, the reporting person exercised a share option for 20,129 Class A ordinary shares at an exercise price of $10.36 per share and acquired these shares. On the same date, they sold 20,129 Class A ordinary shares in broker-dealer trades at a weighted average price of $41.51 per share, with individual trade prices ranging from $41.19 to $41.78. After these transactions, the director beneficially owned 12,546 Class A ordinary shares directly, and held 0 derivative securities following the full exercise of the option, which was fully vested and exercisable. The transactions were made under a Rule 10b5-1 trading plan executed on September 11, 2025.
Kiniksa Pharmaceuticals International, plc reported an insider transaction by its Chief Operating Officer on 12/15/2025. The COO exercised an employee share option to acquire 6,000 Class A Ordinary Shares at an exercise price of $8.83 per share, then sold 12,048 Class A Ordinary Shares at a weighted average price of $41.56 per share through multiple trades.
After these transactions, the reporting person beneficially owned 16,666 Class A Ordinary Shares, held directly. The filing states that the trades were made under a pre-established Rule 10b5-1 trading plan executed on April 29, 2024, and notes that the option involved in this transaction was fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc (KNSA) reported an insider equity transaction by its Chief Operating Officer on Form 4. On 11/17/2025, the COO exercised a share option for 6,500 Class A ordinary shares at an exercise price of $8.83 per share, then sold shares the same day in two broker-executed transactions under a pre-arranged Rule 10b5-1 trading plan dated April 29, 2024.
The sales included 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30, both executed in multiple trades within stated price ranges. After these transactions, the COO directly beneficially owned 22,714 Class A ordinary shares and held 6,000 share options that are fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA): The Chairman & CEO reported bona fide gifts (Code G) of Class A ordinary shares. On 11/12/2025, 111,794 shares were gifted; on 11/13/2025, 60,000 shares were gifted. These entries were at a stated price of $0 per share.
After the transactions, reported holdings were 0 shares direct, and indirect balances included 51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 shares held by The Patel Family Irrevocable Trust of 2025, and 109,795 shares held by The Marina 2016 Irrevocable Trust.
Kiniksa Pharmaceuticals (KNSA) disclosed a Form 4 showing its Chief Medical Officer executed pre‑planned transactions on 10/31/2025 under a Rule 10b5‑1 plan. The officer exercised options for 36,542 Class A ordinary shares at $3.80 and 46,000 shares at $8.83, then sold 82,542 shares at a weighted average price of $37.14 (trade range: $36.80–$37.675). Following these transactions, the filing reports 61,324 shares beneficially owned directly. The options exercised were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO exercised 100 share options at $30.93 and sold 100 Class A Ordinary Shares at $41.00, executed under a Rule 10b5-1 plan dated September 3, 2024. Following these trades, the officer directly owned 31,086 shares and held 19,900 options with an expiration of 09/19/2028. The option was fully vested and exercisable.
Kiniksa Pharmaceuticals International (KNSA) reported a profitable quarter. For Q3 2025, total revenue was $180.855 million, up from $112.214 million a year ago, driven entirely by higher net product revenue from ARCALYST in the U.S. Net income reached $18.435 million versus a loss of $12.693 million last year; diluted EPS was $0.23.
Operating expenses reflected ARCALYST profit sharing with Regeneron, with collaboration expenses at $63.307 million. Cost of goods sold was $20.257 million, R&D $24.166 million, and SG&A $49.104 million. Cash, cash equivalents and short‑term investments totaled $352.102 million as of September 30, 2025, and operating cash flow for the nine months was $84.091 million. Shareholders’ equity increased to $535.383 million from $438.436 million at year‑end.
Year‑to‑date, revenue was $475.437 million (vs. $300.703 million), with net income of $44.806 million (vs. a $34.305 million loss). The company terminated the mavrilimumab license with MedImmune effective May 22, 2025 and mutually terminated the Huadong mavrilimumab agreement; the ARCALYST Huadong agreement remains in place with $31.811 million recorded as non‑current deferred revenue.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
